Amalgamated Bank Raises Holdings in Insulet Corporation (NASDAQ:PODD)

Amalgamated Bank grew its position in shares of Insulet Corporation (NASDAQ:PODD) by 2.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,909 shares of the medical instruments supplier’s stock after purchasing an additional 361 shares during the period. Amalgamated Bank’s holdings in Insulet were worth $3,915,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Horizon Investments LLC grew its position in shares of Insulet by 3.1% during the fourth quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier’s stock valued at $362,000 after purchasing an additional 42 shares in the last quarter. Envestnet Portfolio Solutions Inc. lifted its holdings in shares of Insulet by 2.3% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 2,113 shares of the medical instruments supplier’s stock valued at $552,000 after acquiring an additional 48 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its holdings in shares of Insulet by 5.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,050 shares of the medical instruments supplier’s stock valued at $274,000 after acquiring an additional 50 shares during the last quarter. Sequoia Financial Advisors LLC lifted its holdings in shares of Insulet by 2.4% in the 4th quarter. Sequoia Financial Advisors LLC now owns 2,170 shares of the medical instruments supplier’s stock valued at $566,000 after acquiring an additional 50 shares during the last quarter. Finally, Quadrant Capital Group LLC lifted its holdings in shares of Insulet by 4.9% in the 4th quarter. Quadrant Capital Group LLC now owns 1,092 shares of the medical instruments supplier’s stock valued at $285,000 after acquiring an additional 51 shares during the last quarter.

Insulet Trading Down 0.2%

Shares of Insulet stock opened at $301.14 on Friday. Insulet Corporation has a fifty-two week low of $173.00 and a fifty-two week high of $329.33. The company has a debt-to-equity ratio of 1.21, a quick ratio of 3.63 and a current ratio of 4.47. The firm has a 50-day simple moving average of $302.26 and a two-hundred day simple moving average of $278.56. The company has a market cap of $21.19 billion, a P/E ratio of 54.16, a price-to-earnings-growth ratio of 2.69 and a beta of 1.35.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.21. Insulet had a net margin of 18.29% and a return on equity of 22.25%. The firm had revenue of $569.00 million during the quarter, compared to the consensus estimate of $543.20 million. During the same quarter in the prior year, the firm earned $0.73 EPS. The company’s revenue for the quarter was up 28.8% on a year-over-year basis. As a group, equities analysts predict that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently commented on PODD shares. Truist Financial started coverage on shares of Insulet in a report on Monday, June 16th. They issued a “buy” rating and a $365.00 price target for the company. The Goldman Sachs Group started coverage on shares of Insulet in a report on Friday, May 30th. They issued a “buy” rating and a $380.00 price target for the company. Citigroup reaffirmed a “buy” rating and issued a $380.00 price target (up previously from $320.00) on shares of Insulet in a report on Thursday, May 22nd. Royal Bank Of Canada started coverage on shares of Insulet in a report on Thursday, March 6th. They issued an “outperform” rating and a $340.00 price target for the company. Finally, Barclays increased their price target on shares of Insulet from $234.00 to $266.00 and gave the company an “equal weight” rating in a report on Wednesday, April 30th. Four equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $321.00.

Insider Buying and Selling

In other Insulet news, SVP John W. Kapples sold 5,278 shares of the stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the sale, the senior vice president owned 23,180 shares in the company, valued at approximately $7,382,134.60. This represents a 18.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.39% of the company’s stock.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.